COMMUNIQUÉS West-GlobeNewswire

NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
22/12/2025
Ghent, Belgium, Dec. 22, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, [...]
EUROBIO SCIENTIFIC: REPLACEMENT OF A STATUTORY AUDITOR
22/12/2025
REPLACEMENT OF A STATUTORY AUDITOR Paris, December 22, 2025 – 6:00 pm Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, announces the replacement of one [...]
EUROBIO SCIENTIFIC : REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES
22/12/2025
REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES Paris, le 22 décembre 2025 – 18h00 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2025
22/12/2025
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - November 2025
22/12/2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
22/12/2025
WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 [...]
Vivos Inc Summarizes Progress in its Animal Therapy Division
22/12/2025
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary [...]
BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™
22/12/2025
Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older BURLINGTON, Mass. and [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
22/12/2025
EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to [...]
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc . (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that [...]
Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class Treatments for Chronic Kidney Disease
22/12/2025
Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify has developed oral, small molecules that can potentially reduce calcification by enhancing the [...]
Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus
22/12/2025
AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today opened access to [...]
Nasus Pharma CEO Issues 2025 Letter to Shareholders
22/12/2025
TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal [...]
Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy
22/12/2025
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other [...]
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
22/12/2025
JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today [...]
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
22/12/2025
Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company [...]
Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
22/12/2025
Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels Dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profile [...]
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
22/12/2025
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked [...]
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
22/12/2025
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to support potential [...]

Pages